We are live on ! Find out more
USNA icon

Usana Health Sciences

172 hedge funds and large institutions have $573M invested in Usana Health Sciences in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 58 increasing their positions, 76 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.22% less ownership

Funds ownership: 54.48%53.26% (-1.2%)

5% less funds holding

Funds holding: 182172 (-10)

24% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 76

24% less capital invested

Capital invested by funds: $758M → $573M (-$185M)

35% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 26

44% less call options, than puts

Call options by funds: $22K | Put options by funds: $39K

Holders
172
Holders Change
-10
Holders Change %
-5.49%
% of All Funds
2.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
58
Reduced
76
Closed
26
Calls
$22K
Puts
$39K
Net Calls
-$17K
Net Calls Change
-$17K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$103M -$452K -6,839 -0.4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$83M -$1.1M -16,700 -1%
Renaissance Technologies
3
Renaissance Technologies
New York
$73.3M -$8.2M -124,000 -9%
Pzena Investment Management
4
Pzena Investment Management
New York
$40.4M -$272K -4,116 -0.6%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$31.6M -$198K -2,997 -0.5%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$22.5M -$3.1M -46,963 -10%
State Street
7
State Street
Massachusetts
$22M +$422K +6,381 +2%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$12.5M +$330K +4,994 +2%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$9.6M -$414K -6,264 -4%
Charles Schwab
10
Charles Schwab
California
$9.47M +$746K +11,284 +7%
Invesco
11
Invesco
Georgia
$8.43M -$325K -4,922 -3%
Morgan Stanley
12
Morgan Stanley
New York
$7.95M -$944K -14,282 -9%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$6.71M -$597K -9,025 -7%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$6.71M +$442K +6,693 +6%
Northern Trust
15
Northern Trust
Illinois
$6.7M -$245K -3,704 -3%
Norges Bank
16
Norges Bank
Norway
$6.1M -$90K -1,361 -1%
UBS Group
17
UBS Group
Switzerland
$4.89M +$1.97M +29,755 +52%
JP Morgan Chase
18
JP Morgan Chase
New York
$4.82M +$131K +1,987 +2%
American Century Companies
19
American Century Companies
Missouri
$4.65M +$667K +10,086 +14%
Nordea Investment Management
20
Nordea Investment Management
Sweden
$4.25M -$53.9K -815 -1%
Principal Financial Group
21
Principal Financial Group
Iowa
$3.99M -$428K -6,474 -8%
Hotchkis & Wiley Capital Management
22
Hotchkis & Wiley Capital Management
California
$3.92M -$1.86M -28,190 -29%
Pacer Advisors
23
Pacer Advisors
Pennsylvania
$3.62M -$49.4K -747 -1%
Ameriprise
24
Ameriprise
Minnesota
$3.6M -$470K -7,112 -10%
Assenagon Asset Management
25
Assenagon Asset Management
Luxembourg
$3.31M

USNA Hedge Fund Activity: Q3 2022 in Review

172 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Usana Health Sciences (USNA) for Q3 2022, worth a combined $573M — down 24% from $758M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of USNA and 17 opened new positions — a net loss of 9 holders — while 76 trimmed existing stakes and 58 added.

The largest buyer was UBS Group, adding an estimated $1.97M. The largest seller was Renaissance Technologies, cutting an estimated $8.2M.

  • 172 institutional investors held Usana Health Sciences (USNA) as of Q3 2022, down from 182 in Q2 2022.
  • Funds reported $573M of Usana Health Sciences stock for Q3 2022, down 24% quarter-over-quarter.
  • 17 funds opened new Usana Health Sciences positions in Q3 2022 and 26 closed out, a net change of -9 holders.
  • The largest Usana Health Sciences buyer in Q3 2022 was UBS Group, an estimated $1.97M added.
  • The largest Usana Health Sciences seller in Q3 2022 was Renaissance Technologies, an estimated $8.2M sold.

Based on aggregated 13F filings for Q3 2022.